Pfizer Inc.'s Financial Performance: An Evaluation of Growth and Profitability

Abstract

Based on Pfizer's 2021 annual report, this paper explored whether Pfizer's ac-counting policy is accurate, whether the company's strategic adjustments for the future are achievable, and whether Pfizer's performance is good in com-parison with its industry peers. By analyzing Pfizer's accounting standards, this analysis concluded that Pfizer's accounting policy is relatively accurate. Pfizer adopted a new accounting standard for income taxes that eliminates certain exceptions related to the method of allocating tax for the period. To analyze whether Pfizer's strategic adjustment for the company's future de-velopment is achievable, this paper has analyzed the situation of the general environment in 2022 and 2023 and the characteristics of Pfizer's industry, from which this paper concluded that Pfizer's strategic adjustment is a clear choice, although it requires time and effort. It is worth noting that Pfizer made a significant acquisition in 2021. When comparing Pfizer with its competitors, this paper chose to compare the performance, leverage, and li-quidity of Pfizer with its competitors, each of which contains two to three key ratios, and by comparing these data, this analysis concluded that Pfizer is still outstanding when compared with its competitors, and it is a company that investors can trust.